+

WO1999067252A3 - Derives de l'epothilone, leur synthese et leur utilisation - Google Patents

Derives de l'epothilone, leur synthese et leur utilisation Download PDF

Info

Publication number
WO1999067252A3
WO1999067252A3 PCT/EP1999/004287 EP9904287W WO9967252A3 WO 1999067252 A3 WO1999067252 A3 WO 1999067252A3 EP 9904287 W EP9904287 W EP 9904287W WO 9967252 A3 WO9967252 A3 WO 9967252A3
Authority
WO
WIPO (PCT)
Prior art keywords
absent
single bond
synthesis
alkyl
double bond
Prior art date
Application number
PCT/EP1999/004287
Other languages
English (en)
Other versions
WO1999067252A2 (fr
Inventor
Kyriacos Costa Nicolaou
Nigel Paul King
Maurice Raymond Verscho Finlay
Yun He
Frank Roschangar
Dionisios Vourloumis
Hans Vallberg
Antony Bigot
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Scripps Research Inst
Kyriacos Costa Nicolaou
Nigel Paul King
Maurice Raymond Verscho Finlay
Yun He
Frank Roschangar
Dionisios Vourloumis
Hans Vallberg
Antony Bigot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2334342A priority Critical patent/CA2334342C/fr
Priority to BR9911420-8A priority patent/BR9911420A/pt
Priority to MXPA00012443A priority patent/MXPA00012443A/es
Priority to PL345327A priority patent/PL197648B1/pl
Priority to SI9930943T priority patent/SI1089998T1/sl
Priority to SK1971-2000A priority patent/SK285647B6/sk
Priority to NZ508622A priority patent/NZ508622A/en
Priority to JP2000555904A priority patent/JP4681732B2/ja
Priority to US09/720,070 priority patent/US6531497B1/en
Priority to SK5009-2007A priority patent/SK287864B6/sk
Priority to DE69933767T priority patent/DE69933767T2/de
Priority to EP99931120A priority patent/EP1089998B1/fr
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, Scripps Research Inst, Kyriacos Costa Nicolaou, Nigel Paul King, Maurice Raymond Verscho Finlay, Yun He, Frank Roschangar, Dionisios Vourloumis, Hans Vallberg, Antony Bigot filed Critical Novartis Ag
Priority to IL13978499A priority patent/IL139784A0/xx
Priority to AU47748/99A priority patent/AU757854B2/en
Priority to HU0102711A priority patent/HUP0102711A3/hu
Publication of WO1999067252A2 publication Critical patent/WO1999067252A2/fr
Publication of WO1999067252A3 publication Critical patent/WO1999067252A3/fr
Priority to IL139784A priority patent/IL139784A/en
Priority to NO20006378A priority patent/NO328417B1/no
Priority to HK01109176A priority patent/HK1038358A1/xx
Priority to US10/386,999 priority patent/US7579366B2/en
Priority to CY20061101818T priority patent/CY1105863T1/el
Priority to IL182744A priority patent/IL182744A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des analogues de l'épothilone de formule (I) dans laquelle: R2 est absent ou O; (a) peut être une liaison simple ou double; (b) peut être absent ou une liaison simple; et (c) peut être absent ou une liaison simple, sous réserve que si R2 est O, (b) et (c) soient chacun une liaison simple et (a) soit une liaison simple, que si R2 est absent, (b) et (c) soient absents, et (a) soit une double liaison, et que si (a) est une double liaison, R2, (b) et (c) soient absents; R3 est un radical choisi parmi H, alkyle inférieur, -CH=CH2, -C CH, -CH2F, -CH2Cl, CH2-OH, -CH2-O-(C1-C6 alkyle), et -CH2-S-(C1-C6 alkyle); R4 et R5 sont choisis indépendamment parmi H, méthyle et un groupe protecteur; et R1 est tel que défini dans la spécification. L'invention porte en outre sur un sel d'un composé de formule (I) dans lequel est présent un groupe formateur de sels, et sur la synthèse de l'épothilone E. Ces composés qui présentent notamment une activité inhibitrice de la dépolymérisation des microtubuli, s'avèrent par exemple utiles contre les maladies proliférantes.
PCT/EP1999/004287 1998-06-22 1999-06-21 Derives de l'epothilone, leur synthese et leur utilisation WO1999067252A2 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
DE69933767T DE69933767T2 (de) 1998-06-22 1999-06-21 Epothilonderivate, ihre synthese und verwendung
MXPA00012443A MXPA00012443A (es) 1998-06-22 1999-06-21 Derivados de epotilona y su sintesis y uso.
PL345327A PL197648B1 (pl) 1998-06-22 1999-06-21 Pochodna epotylonu, preparat farmaceutyczny zawierający pochodną epotylonu, zastosowanie pochodnej epotylonu oraz sposób jej wytwarzania
SI9930943T SI1089998T1 (sl) 1998-06-22 1999-06-21 Derivati epotilona, njihova sinteza in uporaba
SK1971-2000A SK285647B6 (sk) 1998-06-22 1999-06-21 Deriváty epotilónu, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie
BR9911420-8A BR9911420A (pt) 1998-06-22 1999-06-21 Derivados de epotilona e sìntese e uso dos mesmos
JP2000555904A JP4681732B2 (ja) 1998-06-22 1999-06-21 エポシロン誘導体ならびにその合成および使用
US09/720,070 US6531497B1 (en) 1998-06-22 1999-06-21 Epothilone derivatives and their synthesis and use
SK5009-2007A SK287864B6 (sk) 1998-06-22 1999-06-21 Epothilone derivatives, pharmaceutical formulation containing thereof, their use and method of synthesis
EP99931120A EP1089998B1 (fr) 1998-06-22 1999-06-21 Derives de l'epothilone, leur synthese et leur utilisation
NZ508622A NZ508622A (en) 1998-06-22 1999-06-21 Epothilone derivatives and their synthesis and use
CA2334342A CA2334342C (fr) 1998-06-22 1999-06-21 Derives de l'epothilone, leur synthese et leur utilisation
IL13978499A IL139784A0 (en) 1998-06-22 1999-06-21 Epothilone derivatives and their synthesis and use
AU47748/99A AU757854B2 (en) 1998-06-22 1999-06-21 Epothilone derivatives and their synthesis and use
HU0102711A HUP0102711A3 (en) 1998-06-22 1999-06-21 Epothilone derivatives and pharmaceutical compositions containing them and process for preparation the same
IL139784A IL139784A (en) 1998-06-22 2000-11-20 Epothilone derivatives, their synthesis and pharmaceutical compositions containing them
NO20006378A NO328417B1 (no) 1998-06-22 2000-12-14 Epotilonderivater samt deres syntese og anvendelse
HK01109176A HK1038358A1 (en) 1998-06-22 2001-12-28 Epothilone derivatives and their synthesis and use.
US10/386,999 US7579366B2 (en) 1998-06-22 2003-03-11 Epothilone derivatives and their synthesis and use
CY20061101818T CY1105863T1 (el) 1998-06-22 2006-12-20 Παραγωγα εποθιλονης και η συνθεση και η χρηση τους
IL182744A IL182744A (en) 1998-06-22 2007-04-23 Epothilone derivatives and their synthesis and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/102,602 US6380394B1 (en) 1996-12-13 1998-06-22 Epothilone analogs
US09/102,602 1998-06-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/102,602 Continuation-In-Part US6380394B1 (en) 1996-12-13 1998-06-22 Epothilone analogs

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/720,070 A-371-Of-International US6531497B1 (en) 1998-06-22 1999-06-21 Epothilone derivatives and their synthesis and use
US09720070 A-371-Of-International 1999-06-21
US10/386,999 Division US7579366B2 (en) 1998-06-22 2003-03-11 Epothilone derivatives and their synthesis and use

Publications (2)

Publication Number Publication Date
WO1999067252A2 WO1999067252A2 (fr) 1999-12-29
WO1999067252A3 true WO1999067252A3 (fr) 2000-03-16

Family

ID=22290705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/004287 WO1999067252A2 (fr) 1998-06-22 1999-06-21 Derives de l'epothilone, leur synthese et leur utilisation

Country Status (28)

Country Link
US (3) US6380394B1 (fr)
EP (2) EP1741715A1 (fr)
JP (1) JP4681732B2 (fr)
KR (3) KR20080045298A (fr)
CN (1) CN1192031C (fr)
AT (1) ATE343573T1 (fr)
AU (1) AU757854B2 (fr)
BR (1) BR9911420A (fr)
CA (1) CA2334342C (fr)
CY (1) CY1105863T1 (fr)
CZ (1) CZ301783B6 (fr)
DE (1) DE69933767T2 (fr)
DK (1) DK1089998T3 (fr)
ES (1) ES2273502T3 (fr)
HK (1) HK1038358A1 (fr)
HU (1) HUP0102711A3 (fr)
ID (1) ID28210A (fr)
IL (3) IL139784A0 (fr)
MX (1) MXPA00012443A (fr)
NO (1) NO328417B1 (fr)
NZ (1) NZ508622A (fr)
PL (1) PL197648B1 (fr)
PT (1) PT1089998E (fr)
RU (1) RU2227142C2 (fr)
SK (2) SK287864B6 (fr)
TR (1) TR200003844T2 (fr)
WO (1) WO1999067252A2 (fr)
ZA (1) ZA200007059B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849651B2 (en) 1996-12-03 2005-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6965034B2 (en) 1996-12-03 2005-11-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0873341T3 (da) 1995-11-17 2004-01-19 Biotechnolog Forschung Gmbh Epothilonderivater, fremstilling og anvendelse
AU753546B2 (en) * 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
DE19820599A1 (de) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
CA2350189A1 (fr) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Matieres et procedes recombinants destines a la production d'epothilone et de derives d'epothilone
AU771089B2 (en) * 1999-02-22 2004-03-11 Bristol-Myers Squibb Company C-21 modified epothilones
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
AU779089B2 (en) 1999-04-15 2005-01-06 Bristol-Myers Squibb Holdings Ireland Unlimited Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU2508201A (en) * 1999-11-24 2001-06-04 Basf Aktiengesellschaft Fungicidal melithiazole derivatives
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
WO2001092255A2 (fr) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Derives d'epothilone, procedes de production et methodes d'utilisation
EP1319011B1 (fr) * 2000-09-22 2012-12-05 Helmholtz-Zentrum für Infektionsforschung GmbH Triazolo-epothilones
IL155306A0 (en) * 2000-10-13 2003-11-23 Univ Mississippi Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
WO2002062338A1 (fr) 2001-01-25 2002-08-15 Bristol-Myers Squibb Company Formulations parenterales contenant des analogues d'epothilone
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
YU58203A (sh) 2001-01-25 2006-08-17 Bristol-Myers Squibb Company Postupci primene epotilonskih analoga za lečenje kancera
KR20040025895A (ko) 2001-02-20 2004-03-26 브리스톨-마이어스스퀴브컴파니 에포틸론 유도체를 사용하는 치료불응성 종양의 치료
KR20040028720A (ko) 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
KR20030084952A (ko) * 2001-02-27 2003-11-01 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) 에포틸론의 분해 및 에티닐 치환된 에포틸론
WO2002072085A1 (fr) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combinaison d'analogues d'epothilones et d'agents chimiotherapeutiques servant au traitement de maladies proliferatives
WO2002098868A1 (fr) * 2001-06-01 2002-12-12 Bristol-Myers Squibb Company Derives d'epothilone
CA2456280A1 (fr) * 2001-08-23 2003-03-06 Novartis Ag Analogues d'epothilone cyclopropyle et cyclobutyle
WO2003026744A1 (fr) * 2001-09-25 2003-04-03 Alcon, Inc. Utilisation d'epothilones et analogues en chirurgie ophtalmique
KR100954625B1 (ko) * 2001-10-25 2010-04-27 노파르티스 아게 선택적 사이클로옥시게나제-2 억제제를 포함하는 조합물
AU2002361022A1 (en) * 2001-12-07 2003-06-17 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
IL162595A0 (en) 2002-01-14 2005-11-20 Novartis Ag Combinations comprising epothilones and antimetabolites
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003218110A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CN100439374C (zh) * 2002-08-02 2008-12-03 诺瓦提斯公司 埃坡霉素衍生物
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN1759115A (zh) * 2002-08-23 2006-04-12 索隆-基特林癌症研究协会 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途
GB0221312D0 (en) * 2002-09-13 2002-10-23 Novartis Ag Organic compounds
CA2695720C (fr) 2002-09-23 2013-04-02 Bristol-Myers Squibb Company Methode de production d'epothilone b par culture de sorangium cellulosum dans un milieu comprenant de l'acide propanoique
CN1297269C (zh) * 2002-10-15 2007-01-31 路易斯安那州州立大学及农业机械学院管理委员会 埃坡霉素衍生物用于治疗甲状旁腺功能亢进的用途
WO2004045518A2 (fr) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1559447A1 (fr) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation d'epothilone pour le traitement de defauts de connectivité neuronale comme par exemple la schizophrenie et l'autisme
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0405898D0 (en) * 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1674098A1 (fr) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Formulations parenterales stables et tolérables des substances de haut réactivité ayant une solubilité basse ou inexistante dans l'eau
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
WO2006122408A1 (fr) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Composes liants de domaine bir
US7893268B2 (en) * 2005-07-27 2011-02-22 University Of Toledo Epithiolone analogues
US8003801B2 (en) * 2005-11-22 2011-08-23 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7653731B2 (en) * 2006-02-24 2010-01-26 Microsoft Corporation Management of connections to external data
EP2029156A4 (fr) * 2006-05-01 2010-07-21 Univ Southern California Polythérapie pour traiter le cancer
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
EP2089411A4 (fr) 2006-12-04 2010-01-27 Univ Illinois Compositions et procédés pour le traitement du cancer avec des cuprédoxines et de l'adn riche en cpg
JP2010518123A (ja) 2007-02-08 2010-05-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をキュプレドキシンで予防するための組成物および方法
WO2008118327A1 (fr) * 2007-03-23 2008-10-02 University Of Toledo Analogues d'épothilone restreints en conformation en tant qu'agents anti-leucémiques
EP2065054A1 (fr) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinaisons comprenant une prostaglandine et leurs utilisations
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanoparticules à surface modifiée
WO2010000817A1 (fr) * 2008-07-03 2010-01-07 Pharma Mar, S.A. Macrolides antitumoraux
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (fr) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Composition polymère stable comprenant un copolymère séquencé d'épothilone et amphiphile
RU2567544C2 (ru) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir домен iap связывающие соединения
JP5881254B2 (ja) 2010-05-18 2016-03-09 セルリアン・ファーマ・インコーポレイテッド 自己免疫疾患およびその他の疾患の治療のための組成物および方法
US8846006B2 (en) 2011-01-20 2014-09-30 Board Of Regents, The University Of Texas System MRI markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
AU2012356894B2 (en) 2011-12-23 2018-01-18 Araris Biotech Ltd. Enzymatic conjugation of polypeptides
EP2872894B1 (fr) 2012-07-13 2019-04-17 Innate Pharma Criblage d'anticorps conjugués
EP2916872B1 (fr) 2012-11-09 2019-02-27 Innate Pharma Etiquettes de reconnaissance pour la conjugaison à médiation par la tgase
US9725477B2 (en) 2012-11-17 2017-08-08 Beijing Fswelcome Technology Development Co., Ltd Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
CA2898996A1 (fr) * 2013-01-23 2014-07-31 The University Of Toledo Agents anticancereux hautement selectifs ciblant le cancer de poumon non a petites cellules et d'autres formes de cancer
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
EP3010547B1 (fr) 2013-06-20 2021-04-21 Innate Pharma Conjugaison enzymatique de polypeptides
CA2914189C (fr) 2013-06-21 2023-03-14 Innate Pharma Conjugaison enzymatique de polypeptides
WO2017066606A1 (fr) * 2015-10-16 2017-04-20 William Marsh Rice University Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci
WO2019092148A1 (fr) 2017-11-10 2019-05-16 Innate Pharma Anticorps avec des résidus de glutamine fonctionnalisés

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022461A1 (fr) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e et f, mode de preparation et application comme agents cytostatiques et phytosanitaires
WO1998025929A1 (fr) * 1996-12-13 1998-06-18 Novartis Ag Analogues d'epothilone
WO1998038192A1 (fr) * 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilones a chaine laterale modifiee

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW221441B (fr) * 1991-01-25 1994-03-01 Taiho Pharmaceutical Co Ltd
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DK0873341T3 (da) 1995-11-17 2004-01-19 Biotechnolog Forschung Gmbh Epothilonderivater, fremstilling og anvendelse
EP0923583A1 (fr) 1996-08-30 1999-06-23 Novartis AG Procede de fabrication d'epothilones, et composes intermediaires obtenus au cours de ce procede
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PT1005465E (pt) 1997-08-09 2007-10-18 Bayer Schering Pharma Ag Novos derivados da epotilona, processo para a sua preparação e sua utilização farmacêutica
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022461A1 (fr) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e et f, mode de preparation et application comme agents cytostatiques et phytosanitaires
WO1998025929A1 (fr) * 1996-12-13 1998-06-18 Novartis Ag Analogues d'epothilone
WO1998038192A1 (fr) * 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilones a chaine laterale modifiee

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
K C NICOLAOU ET AL: "Total syntheses of Epothilones A and B via a macrolactonization-based strategy", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, vol. 119, no. 34, pages 7974 - 7991, XP002110540, ISSN: 0002-7863 *
NICOLAOU K C ET AL: "Total Synthesis of 26-Hydroxy-Epothilone B and Related Analogs via a Macrolactonization Based Strategy", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 54, no. 25, pages 7127-7166, XP004128313, ISSN: 0040-4020 *
NICOLAOU, K. C. ET AL: "Designed epothilones: combinatorial synthesis, tubulin assembly properties, and cytotoxic action against taxol-resistant tumor cells", ANGEW. CHEM., INT. ED. ENGL. (1997), 36(19), 2097-2103, XP002064441 *
NICOLAOU, K. C. ET AL: "Total synthesis of oxazole- and cyclopropane-containing epothilone B analogs by the macrolactonization approach", CHEM.--EUR. J. (1997), 3(12), 1971-1986, XP002110542 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849651B2 (en) 1996-12-03 2005-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6965034B2 (en) 1996-12-03 2005-11-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
USRE41990E1 (en) 1996-12-03 2010-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Also Published As

Publication number Publication date
HUP0102711A3 (en) 2002-09-30
HK1038358A1 (en) 2002-03-15
PL197648B1 (pl) 2008-04-30
SK287864B6 (sk) 2012-02-03
NO20006378D0 (no) 2000-12-14
JP4681732B2 (ja) 2011-05-11
KR20090066332A (ko) 2009-06-23
TR200003844T2 (tr) 2001-04-20
DE69933767T2 (de) 2007-09-13
JP2002518504A (ja) 2002-06-25
SK285647B6 (sk) 2007-05-03
CN1192031C (zh) 2005-03-09
CA2334342A1 (fr) 1999-12-29
HUP0102711A2 (hu) 2001-12-28
DE69933767D1 (de) 2006-12-07
SK19712000A3 (sk) 2001-09-11
IL139784A (en) 2010-05-17
KR20010083060A (ko) 2001-08-31
CA2334342C (fr) 2012-07-17
EP1089998A2 (fr) 2001-04-11
WO1999067252A2 (fr) 1999-12-29
ES2273502T3 (es) 2007-05-01
US7579366B2 (en) 2009-08-25
KR20080045298A (ko) 2008-05-22
NO328417B1 (no) 2010-02-15
IL139784A0 (en) 2002-02-10
RU2227142C2 (ru) 2004-04-20
US6531497B1 (en) 2003-03-11
IL182744A0 (en) 2007-07-24
ZA200007059B (en) 2002-01-30
IL182744A (en) 2010-05-17
DK1089998T3 (da) 2007-01-15
EP1089998B1 (fr) 2006-10-25
NZ508622A (en) 2003-07-25
PT1089998E (pt) 2007-01-31
US6380394B1 (en) 2002-04-30
US20030203938A1 (en) 2003-10-30
PL345327A1 (en) 2001-12-17
CZ20004769A3 (cs) 2001-07-11
MXPA00012443A (es) 2004-12-03
ATE343573T1 (de) 2006-11-15
BR9911420A (pt) 2001-03-20
EP1741715A1 (fr) 2007-01-10
CN1306531A (zh) 2001-08-01
ID28210A (id) 2001-05-10
CZ301783B6 (cs) 2010-06-23
CY1105863T1 (el) 2011-02-02
AU757854B2 (en) 2003-03-06
NO20006378L (no) 2001-02-21
AU4774899A (en) 2000-01-10
KR100864742B1 (ko) 2008-10-22

Similar Documents

Publication Publication Date Title
WO1999067252A3 (fr) Derives de l'epothilone, leur synthese et leur utilisation
TW262474B (fr)
CA2229173A1 (fr) Composes pyrazole anti-parasitaires
DE69736642D1 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
MY115311A (en) Optically active 2 - imidazoline - 5 - one derivatives as fungicides.
NL350055I1 (fr)
AU9107491A (en) 1,4-benzothiazepine derivative
AU4321397A (en) Pyrazolopyridylpyridazinone derivatives and process for preparing the same
DE69505968D1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
GB9202378D0 (en) Inventions relating to fungicidal compositions
CA2356121A1 (fr) Nouveaux derives de propargylether
AU1867792A (en) Improvements in or relating to organic compounds
HUT50337A (en) Process for producing benzoxazine derivatives and pharmaceutical compositions comprising the compounds
WO2000064902A3 (fr) Processus de preparation de precurseurs de calanolide
GB9119281D0 (en) Compound use and preparation
PH30229A (en) Pyridyl substituted benzothiazole compounds which has useful pharmaceutical utility
KR960014780B1 (en) Dental plaque inhibitor composition and its preparation
ATE105565T1 (de) Pradimicinderivate.
GR3035232T3 (en) Thienyl- and furylpyrrole derivatives, their preparation and their use as insecticides and acaricides.
NO303817B1 (no) Tiokarbamatsulfoksydsammensetning for avholdenhet fra inntakelse av etanol
HU900968D0 (en) Algicidal compositions and covering compositions thereof
AU5127996A (en) Substituted 6-r-1,3,4-thiadiazine-2-amines, the use thereof as anaesthetising, cardiovascular and hypometabolic agents, and a pharmaceutical composition containing them

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200100059

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 99807769.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09624843

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 139784

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2000/07059

Country of ref document: ZA

Ref document number: 200007059

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 47748/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 508622

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2334342

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/012443

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999931120

Country of ref document: EP

Ref document number: IN/PCT/2000/841/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2000-4769

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 19712000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020007014546

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000/03844

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1999931120

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09720070

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-4769

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007014546

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 47748/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999931120

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 50092007

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 182744

Country of ref document: IL

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载